DOCSLIB.ORG

Proquest Dissertations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proquest Dissertations urn u Ottawa L'Universitd canadienne Canada's university FACULTE DES ETUDES SUPERIEURES l^^l FACULTY OF GRADUATE AND ET POSTDOCTORALES u Ottawa POSTDOCTORAL STUDIES I.'University emiadienne Canada's university Charles Gyamera-Acheampong AUTEUR DE LA THESE / AUTHOR OF THESIS Ph.D. (Biochemistry) GRADE/DEGREE Biochemistry, Microbiology and Immunology FACULTE, ECOLE, DEPARTEMENT / FACULTY, SCHOOL, DEPARTMENT The Physiology and Biochemistry of the Fertility Enzyme Proprotein Convertase Subtilisin/Kexin Type 4 TITRE DE LA THESE / TITLE OF THESIS M. Mbikay TIRECTWRTDIRICTR^ CO-DIRECTEUR (CO-DIRECTRICE) DE LA THESE / THESIS CO-SUPERVISOR EXAMINATEURS (EXAMINATRICES) DE LA THESE/THESIS EXAMINERS A. Basak G. Cooke F .Kan V. Mezl Gary W. Slater Le Doyen de la Faculte des etudes superieures et postdoctorales / Dean of the Faculty of Graduate and Postdoctoral Studies Library and Archives Bibliotheque et 1*1 Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington OttawaONK1A0N4 Ottawa ON K1A 0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-59504-6 Our file Notre reference ISBN: 978-0-494-59504-6 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library and permettant a la Bibliotheque et Archives Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par I'lnternet, prefer, telecommunication or on the Internet, distribuer et vendre des theses partout dans le loan, distribute and sell theses monde, a des fins commerciales ou autres, sur worldwide, for commercial or non­ support microforme, papier, electronique et/ou commercial purposes, in microform, autres formats. paper, electronic and/or any other formats. The author retains copyright L'auteur conserve la propriete du droit d'auteur ownership and moral rights in this et des droits moraux qui protege cette these. Ni thesis. Neither the thesis nor la these ni des extra its substantiels de celle-ci substantial extracts from it may be ne doivent etre imprimes ou autrement printed or otherwise reproduced reproduits sans son autorisation. without the author's permission. In compliance with the Canadian Conformement a la loi canadienne sur la Privacy Act some supporting forms protection de la vie privee, quelques may have been removed from this formulaires secondaires ont ete enleves de thesis. cette these. While these forms may be included Bien que ces formulaires aient inclus dans in the document page count, their la pagination, il n'y aura aucun contenu removal does not represent any loss manquant. of content from the thesis. 1+1 Canada THE PHYSIOLOGY AND BIOCHEMISTRY OF THE FERTILITY ENZYME PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 4 Charles Gyamera-Acheampong Thesis submitted to the Faculty of Graduate and Postdoctoral Studies in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Biochemistry Department of Biochemistry, Microbiology, and Immunology Faculty of Medicine University of Ottawa January 2009 © Charles Gyamera-Acheampong, Ottawa, Canada, 2009 DEDICATION This thesis is dedicated to my deceased daughter, Harriet Ama Serwaa ii ABSTRACT This three-manuscript thesis focuses on the physiology and biochemistry of the fertility enzyme, Proprotein Convertase Subtilisin-Kexin type 4 (PCSK4). Efforts to develop effective, safe, and reversible methods of non-hormonal contraception especially for men have focussed either on sperm surface proteins involved in the functional maturation of sperm or on those responsible for sperm-egg interactions. PCSK4 is one of such proteins. It is a member of a family of serine endoproteinases involved in the proteolytic maturation of a wide array of inactive precursor proteins to their bioactive forms. It is primarily expressed in the gonads, and inactivation of its gene in mice causes male infertility and female subfertility. The first paper dealt with the reproductive function of PCSK4 by studying its subcellular localisation in testicular epithelium and on intact sperm, as well as its relevance for sperm acquisition of fertilising ability. PCSK4 was detected in the acrosomal granules of round spermatids, in the acrosomal ridges of elongated spermatids, and on the sperm plasma membrane overlying the acrosome. Sperm from PCSK4-null mice underwent capacitation at a faster rate, they were induced to acrosome-react by lower concentrations of zona pellucida, and possessed egg-binding ability which was only half that of wildtype sperm. The second paper explored the molecular basis of the ability of PCSK4-null sperm to undergo capacitation at a much faster rate than WT sperm, as well as their reduced egg- binding ability. It focussed primarily on sperm protein tyrosine phosphorylation and the proteolytic processing of the sperm-egg ligands ADAM2 and ADAM3. During sperm capacitation, proteins undergo more tyrosine phosphorylation and more ADAM2 proteolytic processing in PCSK4-null sperm than in WT sperm. Thus, alterations in signal transduction iii and proteolytic processing during capacitation may underlie the fertilisation incompetence of PCSK4-null sperm. The third paper investigated the biosynthesis, maturation, and transport of PCSK4. Mouse PCSK4 was identified to be tightly bound through hydrophobic interactions to water- insoluble or detergent-soluble components of the plasma membrane overlying the acrosome. Also human proPCSK4, cloned from human embryonic kidney cells (HEK293), is slightly converted into its active mature form, and it is probably retained inside the ER where it associates with Glucose-regulated protein 78/Immunogen Binding Protein (GRP78/BiP). iv ACKNOWLEDGEMENTS I would like to express my profound gratitude to my supervisor, Dr. Majambu Mbikay, for his immense contribution towards the completion of this thesis. He devoted his time and energy, as well as sought for financial support for almost the entire duration of the program. I am also grateful to the remaining members of my thesis advisory committee: Dr. Mary Alice Hefford and Dr. Fraser Scott, for their comments and suggestions which have improved the quality of this thesis. In particular, I am indebted to Dr. Mary Alice Hefford for the time she took, amidst a very tight schedule, in editing the second draft of the thesis. Worthy of appreciation are Drs. Gunther Schmidt, Ajoy Basak, Janice Mayne, Ms. Francine Sirois, Mrs. Adrianna Gambarotta, Mr. Andrew Chen, and Ms. Nathalie Scamuffa for their valuable contributions. I am very grateful to Natural Sciences and Engineering Research Council of Canada for providing the financial support needed to carry out this study. I would like to extend my profound appreciation to my fellow graduate students in the Department of Biochemistry, Microbiology, and Immunology for the friendship and interactions we shared. I will particularly like to mention Hongbin Xu. My thanks further go to the support staff of BMI and the Chronic Disease Program of the Ottawa Hospital: Ms. Carol Ann Kelly, Ms. Nicole Trudel, Mrs. JoAnn McDonald, and Ms. Denise Joanisse for their extreme patience in dealing with all the needs and requests of graduate students. I would never forget the support and prayers of Pastor Andrew Aryee, Church/family members, friends, and loved ones both far and near. May the Lord richly bless you all for the great interest you showed in my studies. Last but not the least, to Mrs. Gyamera-Acheampong A., I say, a million thanks. As if having to support me spiritually, emotionally, and financially were not enough, you endured v the long hours I had to stay away from home so as to be in the laboratory. You might not be aware, but I want you to know that your love and encouragement contributed immensely to the successful completion of this thesis. I cannot, within the page limitations, thank everyone that has made a contribution to this thesis, but I do acknowledge in my heart, all contributions, both great and small. vi TABLE OF CONTENTS DEDICATION ii ABSTRACT iii ACKNOWLEDGEMENTS v TABLE OF CONTENTS vii LIST OF ABBREVIATIONS xi LIST OF FIGURES xv LIST OF TABLES xviii I. INTRODUCTION 1 1.1. NEED TO CONTROL WORLD POPULATION 1 1.2. HORMONAL CONTRACEPTION 3 1.2.1. Mode of action and efficacy of hormonal contraceptives 4 1.2.2. Side effects of hormonal contraception 4 1.3. NON-HORMONAL CONTRACEPTION 6 1.3.1. Utilised by women 6 1.3.2. Utilised by men 6 1.3.2.1. Vasectomy 7 1.3.2.2. Condoms and withdrawals 8 1.3.3. Experimental chemical contraceptives 8 1.3.3.1. Gossypol 8 1.3.3.2. NB-DNJ 10 1.3.4. Experimental immunocontraception 12 1.3.4.1. Anti-sperm antibodies 12 1.3.4.2. Search for contraceptive immunogens 13 1.3.4.3. Eppin 18 1.3.4.4. Recent progress in immunocontraception research 18 1.3.4.2.1. Fertilin a (ADAM1) 19 vii 1.3.4.2.2. Fertilin p (ADAM2) 20 1.3.4.2.3. Cyritestin (ADAM3) 20 1.3.4.2.4. Hyaluronidase (PH-20) 21 1.3.4.2.5. Lactate dehydrogenase C4 (LDH-C4) 21 1.3.4.2.6. Sperm Antigen 10 (SP-10) 22 1.3.4.2.7. Fertilisation Antigen-1 (FA-1) 22 1.3.4.2.8. Rabbit Sperm Autoantigens family (RSA family) 23 1.4. SPERM FUNCTIONAL MATURATION AND INTERACTION WITH EGGS 23 1.4.1. Protein phosphorylation 23 1.4.2. Sperm capacitation 24 1.4.3. Sperm-egg interaction 25 1.5. BIOCHEMISTRY AND BIOLOGY OF PCSK4 27 1.5.1. Limited endoproteolysis as a regulatory mechanism 27 1.5.2. Proprotein convertases 27 1.5.2.1. The PCSK family 27 1.5.2.2. PCSK functional domains 28 1.5.2.3. PCSK cleavage specificities 31 1.5.3. PCSK4: A Gonadal Convertase 32 1.5.3.1. Structure, expression, and activity 32 1.5.3.2.
Load more

Recommended publications
  • Identification of an Alpha-1 Antitrypsin Variant with Enhanced Specificity For
    www.nature.com/scientificreports OPEN Identifcation of an alpha‑1 antitrypsin variant with enhanced specifcity for factor XIa by phage display, bacterial expression, and combinatorial mutagenesis Varsha Bhakta1, Mostafa Hamada2, Amy Nouanesengsy2, Jessica Lapierre2, Darian L. Perruzza2 & William P. Shefeld1,2* Coagulation Factor XIa (FXIa) is an emerging target for antithrombotic agent development. The M358R variant of the serpin alpha‑1 antitrypsin (AAT) inhibits both FXIa and other proteases. Our aim was to enhance the specifcity of AAT M358R for FXIa. We randomized two AAT M358R phage display libraries at reactive centre loop positions P13‑P8 and P7‑P3 and biopanned them with FXIa. A bacterial expression library randomized at P2′‑P3′ was also probed. Resulting novel variants were expressed as recombinant proteins in E. coli and their kinetics of FXIa inhibition determined. The most potent FXIa‑inhibitory motifs were: P13‑P8, HASTGQ; P7‑P3, CLEVE; and P2‑P3′, PRSTE (respectively, novel residues bolded). Selectivity for FXIa over thrombin was increased up to 34‑fold versus AAT M358R for these single motif variants. Combining CLEVE and PRSTE motifs in AAT‑RC increased FXIa selectivity for thrombin, factors XIIa, Xa, activated protein C, and kallikrein by 279‑, 143‑, 63‑, 58‑, and 36‑fold, respectively, versus AAT M358R. AAT‑RC lengthened human plasma clotting times less than AAT M358R. AAT‑RC rapidly and selectively inhibits FXIa and is worthy of testing in vivo. AAT specifcity can be focused on one target protease by selection in phage and bacterial systems coupled with combinatorial mutagenesis. Trombosis, the blockage of intact blood vessels by occlusive clots, continues to impose a heavy clinical burden, and is responsible for one quarter of deaths world-wide1.
    [Show full text]
  • Gene Expression of Prohormone and Proprotein Convertases in the Rat CNS: a Comparative in Situ Hybridization Analysis
    The Journal of Neuroscience, March 1993. 73(3): 1258-1279 Gene Expression of Prohormone and Proprotein Convertases in the Rat CNS: A Comparative in situ Hybridization Analysis Martin K.-H. Schafer,i-a Robert Day,* William E. Cullinan,’ Michel Chri?tien,3 Nabil G. Seidah,* and Stanley J. Watson’ ‘Mental Health Research Institute, University of Michigan, Ann Arbor, Michigan 48109-0720 and J. A. DeSeve Laboratory of *Biochemical and 3Molecular Neuroendocrinology, Clinical Research Institute of Montreal, Montreal, Quebec, Canada H2W lR7 Posttranslational processing of proproteins and prohor- The participation of neuropeptides in the modulation of a va- mones is an essential step in the formation of bioactive riety of CNS functions is well established. Many neuropeptides peptides, which is of particular importance in the nervous are synthesized as inactive precursor proteins, which undergo system. Following a long search for the enzymes responsible an enzymatic cascade of posttranslational processing and mod- for protein precursor cleavage, a family of Kexin/subtilisin- ification events during their intracellular transport before the like convertases known as PCl, PC2, and furin have recently final bioactive products are secreted and act at either pre- or been characterized in mammalian species. Their presence postsynaptic receptors. Initial endoproteolytic cleavage occurs in endocrine and neuroendocrine tissues has been dem- C-terminal to pairs of basic amino acids such as lysine-arginine onstrated. This study examines the mRNA distribution of (Docherty and Steiner, 1982) and is followed by the removal these convertases in the rat CNS and compares their ex- of the basic residues by exopeptidases. Further modifications pression with the previously characterized processing en- can occur in the form of N-terminal acetylation or C-terminal zymes carboxypeptidase E (CPE) and peptidylglycine a-am- amidation, which is essential for the bioactivity of many neu- idating monooxygenase (PAM) using in situ hybridization ropeptides.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Gene Symbol Category ACAN ECM ADAM10 ECM Remodeling-Related ADAM11 ECM Remodeling-Related ADAM12 ECM Remodeling-Related ADAM15 E
    Supplementary Material (ESI) for Integrative Biology This journal is (c) The Royal Society of Chemistry 2010 Gene symbol Category ACAN ECM ADAM10 ECM remodeling-related ADAM11 ECM remodeling-related ADAM12 ECM remodeling-related ADAM15 ECM remodeling-related ADAM17 ECM remodeling-related ADAM18 ECM remodeling-related ADAM19 ECM remodeling-related ADAM2 ECM remodeling-related ADAM20 ECM remodeling-related ADAM21 ECM remodeling-related ADAM22 ECM remodeling-related ADAM23 ECM remodeling-related ADAM28 ECM remodeling-related ADAM29 ECM remodeling-related ADAM3 ECM remodeling-related ADAM30 ECM remodeling-related ADAM5 ECM remodeling-related ADAM7 ECM remodeling-related ADAM8 ECM remodeling-related ADAM9 ECM remodeling-related ADAMTS1 ECM remodeling-related ADAMTS10 ECM remodeling-related ADAMTS12 ECM remodeling-related ADAMTS13 ECM remodeling-related ADAMTS14 ECM remodeling-related ADAMTS15 ECM remodeling-related ADAMTS16 ECM remodeling-related ADAMTS17 ECM remodeling-related ADAMTS18 ECM remodeling-related ADAMTS19 ECM remodeling-related ADAMTS2 ECM remodeling-related ADAMTS20 ECM remodeling-related ADAMTS3 ECM remodeling-related ADAMTS4 ECM remodeling-related ADAMTS5 ECM remodeling-related ADAMTS6 ECM remodeling-related ADAMTS7 ECM remodeling-related ADAMTS8 ECM remodeling-related ADAMTS9 ECM remodeling-related ADAMTSL1 ECM remodeling-related ADAMTSL2 ECM remodeling-related ADAMTSL3 ECM remodeling-related ADAMTSL4 ECM remodeling-related ADAMTSL5 ECM remodeling-related AGRIN ECM ALCAM Cell-cell adhesion ANGPT1 Soluble factors and receptors
    [Show full text]
  • Protein Disulfide Isomerase Homolog PDILT Is Required for Quality Control
    Correction DEVELOPMENTAL BIOLOGY Correction for “Protein disulfide isomerase homolog PDILT is required for quality control of sperm membrane protein ADAM3 and male infertility,” by Keizo Tokuhiro, Masahito Ikawa, Adam M. Benham, and Masaru Okabe, which appeared in issue 10, March 6, 2012, of Proc Natl Acad Sci USA (109: 3850–3855; first published February 22, 2012; 10.1073/pnas. 1117963109). The authors note that the title appeared incorrectly. The title should instead appear as “Protein disulfide isomerase homolog PDILT is required for quality control of sperm membrane protein ADAM3 and male fertility.” The online version has been corrected. www.pnas.org/cgi/doi/10.1073/pnas.1204275109 CORRECTION www.pnas.org PNAS | April 10, 2012 | vol. 109 | no. 15 | 5905 Downloaded by guest on September 24, 2021 Protein disulfide isomerase homolog PDILT is required for quality control of sperm membrane protein ADAM3 and male fertility Keizo Tokuhiroa, Masahito Ikawaa,1, Adam M. Benhama,b, and Masaru Okabea,c,d aResearch Institute for Microbial Diseases, cGraduate School of Pharmaceutical Sciences, and dImmunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan; and bSchool of Biological and Biomedical Sciences, Durham University, Durham DH1 3LE, United Kingdom Edited by Ryuzo Yanagimachi, Institute for Biogenesis Research, University of Hawaii, Honolulu, HI, and approved January 31, 2012 (received for review November 1, 2011) A disintegrin and metalloproteinase 3 (ADAM3) is a sperm mem- misfolded proteins. Whereas homologous lectin chaperones, brane protein critical for both sperm migration from the uterus calnexin/calreticulin (CANX/CALR), chiefly mediate nascent into the oviduct and sperm primary binding to the zona pellucida glycoprotein folding in the somatic cells (14), testicular germ (ZP).
    [Show full text]
  • The Emerging Role of Matrix Metalloproteases of the ADAM Family in Male Germ Cell Apoptosis
    review REVIEW Spermatogenesis 1:3, 195-208; July/August/September 2011; © 2011 Landes Bioscience The emerging role of matrix metalloproteases of the ADAM family in male germ cell apoptosis Ricardo D. Moreno,* Paulina Urriola-Muñoz and Raúl Lagos-Cabré Departamento de Fisiología; Pontificia Universidad Católica de Chile; Santiago, Chile Key words: spermatogenesis, apoptosis, metalloprotease, infertility Constitutive germ cell apoptosis during mammalian sperm- Despite that some data suggest that germ cell apoptosis is autono- atogenesis is a key process for controlling sperm output and to mous (independent of the environment), the role of the Sertoli eliminate damaged or unwanted cells. An increase or decrease cell should not be disregarded, because it may provide important in the apoptosis rate has deleterious consequences and leads survival and/or dead clues to germ cells (see below). Germ cell to low sperm production. Apoptosis in spermatogenesis has been widely studied, but the mechanism by which it is induced apoptosis has been shown to play an important role in control- under physiological or pathological conditions has not been ling sperm output in many species, and in humans it has been 5-10 clarified. We have recently identified the metalloprotease related to infertility. Additionally, it has been proposed that ADAM17 (TACE) as a putative physiological inducer of germ the purported decline in global sperm production is caused by cell apoptosis. The mechanisms involved in regulating the environmental xenoestrogens that induce germ cell apoptosis.11 shedding of the ADAM17 extracellular domain are still far In the same way, a modern lifestyle and the use of underwear has from being understood, although they are important in order been proposed to induce elevated scrotal temperature that may to understand cell-cell communications.
    [Show full text]
  • Studies of Structure and Function of Tripeptidyl-Peptidase II
    Till familj och vänner List of Papers This thesis is based on the following papers, which are referred to in the text by their Roman numerals. I. Eriksson, S.; Gutiérrez, O.A.; Bjerling, P.; Tomkinson, B. (2009) De- velopment, evaluation and application of tripeptidyl-peptidase II se- quence signatures. Archives of Biochemistry and Biophysics, 484(1):39-45 II. Lindås, A-C.; Eriksson, S.; Josza, E.; Tomkinson, B. (2008) Investiga- tion of a role for Glu-331 and Glu-305 in substrate binding of tripepti- dyl-peptidase II. Biochimica et Biophysica Acta, 1784(12):1899-1907 III. Eklund, S.; Lindås, A-C.; Hamnevik, E.; Widersten, M.; Tomkinson, B. Inter-species variation in the pH dependence of tripeptidyl- peptidase II. Manuscript IV. Eklund, S.; Kalbacher, H.; Tomkinson, B. Characterization of the endopeptidase activity of tripeptidyl-peptidase II. Manuscript Paper I and II were published under maiden name (Eriksson). Reprints were made with permission from the respective publishers. Contents Introduction ..................................................................................................... 9 Enzymes ..................................................................................................... 9 Enzymes and pH dependence .............................................................. 11 Peptidases ................................................................................................. 12 Serine peptidases ................................................................................. 14 Intracellular protein
    [Show full text]
  • The Human Genome Project
    TO KNOW OURSELVES ❖ THE U.S. DEPARTMENT OF ENERGY AND THE HUMAN GENOME PROJECT JULY 1996 TO KNOW OURSELVES ❖ THE U.S. DEPARTMENT OF ENERGY AND THE HUMAN GENOME PROJECT JULY 1996 Contents FOREWORD . 2 THE GENOME PROJECT—WHY THE DOE? . 4 A bold but logical step INTRODUCING THE HUMAN GENOME . 6 The recipe for life Some definitions . 6 A plan of action . 8 EXPLORING THE GENOMIC LANDSCAPE . 10 Mapping the terrain Two giant steps: Chromosomes 16 and 19 . 12 Getting down to details: Sequencing the genome . 16 Shotguns and transposons . 20 How good is good enough? . 26 Sidebar: Tools of the Trade . 17 Sidebar: The Mighty Mouse . 24 BEYOND BIOLOGY . 27 Instrumentation and informatics Smaller is better—And other developments . 27 Dealing with the data . 30 ETHICAL, LEGAL, AND SOCIAL IMPLICATIONS . 32 An essential dimension of genome research Foreword T THE END OF THE ROAD in Little has been rapid, and it is now generally agreed Cottonwood Canyon, near Salt that this international project will produce Lake City, Alta is a place of the complete sequence of the human genome near-mythic renown among by the year 2005. A skiers. In time it may well And what is more important, the value assume similar status among molecular of the project also appears beyond doubt. geneticists. In December 1984, a conference Genome research is revolutionizing biology there, co-sponsored by the U.S. Department and biotechnology, and providing a vital of Energy, pondered a single question: Does thrust to the increasingly broad scope of the modern DNA research offer a way of detect- biological sciences.
    [Show full text]
  • Relevance of Platelet Desialylation and Thrombocytopenia In
    Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence Annabelle Dupont, Christelle Soukaseum, Mathilde Cheptou, Frédéric Adam, Thomas Nipoti, Marc-Damien Lourenco-Rodrigues, Paulette Legendre, Valérie Proulle, Antoine Rauch, Charlotte Kawecki, et al. To cite this version: Annabelle Dupont, Christelle Soukaseum, Mathilde Cheptou, Frédéric Adam, Thomas Nipoti, et al.. Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclin- ical and clinical evidence. Haematologica, Ferrata Storti Foundation, 2019, pp.haematol.2018.206250. 10.3324/haematol.2018.206250. hal-02347340 HAL Id: hal-02347340 https://hal.archives-ouvertes.fr/hal-02347340 Submitted on 5 Nov 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Published Ahead of Print on February 28, 2019, as doi:10.3324/haematol.2018.206250. Copyright 2019 Ferrata Storti Foundation. Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence by Annabelle Dupont, Christelle Soukaseum, Mathilde Cheptou, Frédéric Adam, Thomas Nipoti, Marc-Damien Lourenco-Rodrigues, Paulette Legendre, Valérie Proulle, Antoine Rauch, Charlotte Kawecki, Marijke Bryckaert, Jean-Philippe Rosa, Camille Paris, Catherine Ternisien, Pierre Boisseau, Jenny Goudemand, Delphine Borgel, Dominique Lasne, Pascal Maurice, Peter J.
    [Show full text]
  • Protein C Product Monograph 1995 COAMATIC® Protein C Protein C
    Protein C Product Monograph 1995 COAMATIC® Protein C Protein C Protein C, Product Monograph 1995 Frank Axelsson, Product Information Manager Copyright © 1995 Chromogenix AB. Version 1.1 Taljegårdsgatan 3, S-431 53 Mölndal, Sweden. Tel: +46 31 706 20 00, Fax: +46 31 86 46 26, E-mail: [email protected], Internet: www.chromogenix.se COAMATIC® Protein C Protein C Contents Page Preface 2 Introduction 4 Determination of protein C activity with 4 snake venom and S-2366 Biochemistry 6 Protein C biochemistry 6 Clinical Aspects 10 Protein C deficiency 10 Assay Methods 13 Protein C assays 13 Laboratory aspects 16 Products 17 Diagnostic kits from Chromogenix 17 General assay procedure 18 COAMATIC® Protein C 19 References 20 Glossary 23 3 Protein C, version 1.1 Preface The blood coagulation system is carefully controlled in vivo by several anticoagulant mechanisms, which ensure that clot propagation does not lead to occlusion of the vasculature. The protein C pathway is one of these anticoagulant systems. During the last few years it has been found that inherited defects of the protein C system are underlying risk factors in a majority of cases with familial thrombophilia. The factor V gene mutation recently identified in conjunction with APC resistance is such a defect which, in combination with protein C deficiency, increases the thrombosis risk considerably. The Chromogenix Monographs [Protein C and APC-resistance] give a didactic and illustrated picture of the protein C environment by presenting a general view of medical as well as technical matters. They serve as an excellent introduction and survey to everyone who wishes to learn quickly about this field of medicine.
    [Show full text]
  • PROTEIN C DEFICIENCY 1215 Adulthood and a Large Number of Children and Adults with Protein C Mutations [6,13]
    Haemophilia (2008), 14, 1214–1221 DOI: 10.1111/j.1365-2516.2008.01838.x ORIGINAL ARTICLE Protein C deficiency N. A. GOLDENBERG* and M. J. MANCO-JOHNSON* *Hemophilia & Thrombosis Center, Section of Hematology, Oncology, and Bone Marrow Transplantation, Department of Pediatrics, University of Colorado Denver and The ChildrenÕs Hospital, Aurora, CO; and Division of Hematology/ Oncology, Department of Medicine, University of Colorado Denver, Aurora, CO, USA Summary. Severe protein C deficiency (i.e. protein C ment of acute thrombotic events in severe protein C ) activity <1 IU dL 1) is a rare autosomal recessive deficiency typically requires replacement with pro- disorder that usually presents in the neonatal period tein C concentrate while maintaining therapeutic with purpura fulminans (PF) and severe disseminated anticoagulation; protein C replacement is also used intravascular coagulation (DIC), often with concom- for prevention of these complications around sur- itant venous thromboembolism (VTE). Recurrent gery. Long-term management in severe protein C thrombotic episodes (PF, DIC, or VTE) are common. deficiency involves anticoagulation with or without a Homozygotes and compound heterozygotes often protein C replacement regimen. Although many possess a similar phenotype of severe protein C patients with severe protein C deficiency are born deficiency. Mild (i.e. simple heterozygous) protein C with evidence of in utero thrombosis and experience deficiency, by contrast, is often asymptomatic but multiple further events, intensive treatment and may involve recurrent VTE episodes, most often monitoring can enable these individuals to thrive. triggered by clinical risk factors. The coagulopathy in Further research is needed to better delineate optimal protein C deficiency is caused by impaired inactiva- preventive and therapeutic strategies.
    [Show full text]
  • Lab Dept: Coagulation Test Name: PROTEIN C CHROMOGENIC
    Lab Dept: Coagulation Test Name: PROTEIN C CHROMOGENIC General Information Lab Order Codes: PRC Protein C Activity Assay; Protein C Immunologic Assay Synonyms: 85303 – Clotting inhibitors or anticoagulants; Protein C activity CPT Codes: Test Includes: Protein C activity Logistics Protein C, along with its cofactor Protein S, acts as a potent anticoagulant Test Indications: by destroying activated Factors 5 and 8. It also stimulates the fibrinolytic system. It is Vitamin K dependent, therefore it is decreased in coumadin therapy or Vitamin K deficiency. Protein C deficiency is a risk factor for thromboembolism. Severe deficiency may cause purpura fulminans in neonates. Incident to a thrombotic event, both procoagulant and regulatory coagulation proteins may be lower than basal state due to excessive consumption or higher than basal state from reactive overproduction. Therefore, it is best not to test for Protein C deficiency during an acute thrombotic event. The Protein C antigen test determines the amount of the molecule present, not its functionality. The Protein C Chromogenic (activity) assay determines the functionality. Therefore, the Protein C Chromogenic (activity) assay is the preferred method. Lab Testing Sections: Coagulation (Minneapolis Campus) Phone Numbers: MIN Lab: 612-813-6280 STP Lab: 651-220-6550 Test Availability: Daily, 24 hours Turnaround Time: 1 – 7 days, performed on Fridays Special Instructions: Elective testing for Protein C deficiency is best done at least 30 days after cessation of Coumadin® therapy. Protein C may be reduced during an acute event (thrombotic, surgical, etc.) therefore it is preferable not to test for it during this time. However a normal value at the time of an acute event excludes a congenital deficiency.
    [Show full text]